Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France
Fewer than half of eligible lung cancer patients receive genetic testing for HER2, revealing a gap where targeted drugs remain underused in real practice.
This nationwide French real-world study reveals that fewer than half of eligible NSCLC patients received HER2 testing, and most HER2-mutant patients received non-targeted first-line treatment despite emerging options. The data document the real-world implementation gap for HER2-targeted therapy (e.g., T-DXd) in a precision oncology-relevant driver mutation.
What the study was
- Study design
- Retrospective cohort study (Epidemio-Strategy and Medical Economics Lung Cancer database, NCT03848052)
- Population
- Patients with locally advanced or metastatic NSCLC in France (Jan 2015–Dec 2020, follow-up to Apr 2022); nonsquamous or squamous without smoking history
- Sample size
- 18069
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Cancer Medicine
Why it surfaced
Large real-world dataset (n=18,069) documenting HER2 testing gaps in NSCLC. AstraZeneca-sponsored but uses independent national registry. Directly implementable: supports routine HER2 NGS testing as precision oncology standard.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.